Phyteau
Phyteau is a biotech spin-out from Cedars‑Sinai Medical Center, Caltech and UCLA developing oral, incretin‑based therapeutics for metabolic diseases (diabetes, obesity, NASH/NAFLD, prediabetes). The company’s approach focuses on activating the enteroendocrine system to induce release of hormones (GLP‑1, PYY, OXM, CCK) and on gut‑restricted designs intended to limit systemic exposure.
Industries
Nr. of Employees
small (1-50)
Products
Oral incretin‑based therapeutic (development program)
An orally administered therapeutic approach designed to activate gut enteroendocrine hormones to improve blood glucose control and increase satiety for treatment of diabetes, obesity and related metabolic conditions; described as a program under development.
Phyteau
Phyteau is a powerful weight loss and diabetes pill which drives better outcomes at a lower cost compared to current injectable, GLP-1 products. It activates the body’s metabolic hormone system to release therapeutic levels of key hormones, including GLP-1, PYY, OXM and CCK, to improve blood sugar processing, reduce blood sugar peaks after meals and increase satiety. The therapeutics work inside the gut and are designed to restrict systemic exposure producing an exceptional safety profile.
Oral incretin‑based therapeutic (development program)
An orally administered therapeutic approach designed to activate gut enteroendocrine hormones to improve blood glucose control and increase satiety for treatment of diabetes, obesity and related metabolic conditions; described as a program under development.
Phyteau
Phyteau is a powerful weight loss and diabetes pill which drives better outcomes at a lower cost compared to current injectable, GLP-1 products. It activates the body’s metabolic hormone system to release therapeutic levels of key hormones, including GLP-1, PYY, OXM and CCK, to improve blood sugar processing, reduce blood sugar peaks after meals and increase satiety. The therapeutics work inside the gut and are designed to restrict systemic exposure producing an exceptional safety profile.
Services
Research collaborations with academic and clinical institutions to advance metabolic therapeutics from discovery toward clinical evaluation.
Research collaborations with academic and clinical institutions to advance metabolic therapeutics from discovery toward clinical evaluation.
Expertise Areas
- Metabolic disease therapeutics
- Incretin‑based drug discovery
- Enteroendocrine modulation
- Translational medicine
Key Technologies
- Enteroendocrine modulation
- Incretin hormone modulation (GLP‑1, PYY, OXM, CCK)
- Gut‑restricted drug design
- Molecular/receptor pharmacology